PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRV
Post# of 77
(Total Views: 156)
Posted On: 02/22/2018 7:54:58 PM
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Sol-Gel Nose-to-Brain Delivery System of Cannabinoids
- Universally-patient friendly, meaning formulations that can be used in children and adults alike
- Transport of drugs through blood-brain barrier marks top priority for researchers
- North American legal cannabis market projected at more than $24 billion by 2021
- Global market for pain management, drugs and devices estimated at over $61 billion by 2023
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is a Vancouver-based health sciences company dedicated to research and development of innovative, organic and Nature Identical™ options for preventive and curative therapies for a wide array of devastating medical conditions. Developing what the company believes will be the first U.S. Food and Drug Administration-approved cannabidiol (CBD)-soluble gel product to deliver the therapeutic benefits of CBD directly to the central nervous system (CNS) is a top priority for PreveCeutical Chief Researcher Officer Dr. Harry Parekh, who is based at the University of Queensland, Australia, School of Pharmacy (http://nnw.fm/DciL0).
Breaking through the blood-brain barrier, which functions as the last line of defense for the body’s most vital organ, is a prime research target, as noted in a May 2017 article published by The Pharmaceutical Journal (http://nnw.fm/qDr3K). Delivering life-saving drugs directly to the brain to treat complex brain disorders such as Alzheimer’s, Parkinson’s, epilepsy and depression in a safe and effective manner continues to be a major topic of discussion and compelling research around the world (http://nnw.fm/Suw9U). The need for a solution, a way to present a medication directly where it will do the most good with the fewest side effects, is a key driver for Dr. Parekh and his research collaborators as they continue their work on cannabinoids, formulating them into Sol-gels for further testing.
PreveCeutical’s proprietary Sol-gel formulations begin as a liquid that is administrated into the nose, which then forms a gel as it is warmed in the nasal cavity where it can then be absorbed. This effectively bypasses the stomach and intestines – eliminating first pass metabolism – and may dramatically improve bioavailability, even compared to nasal sprays and newer delivery systems. This nose-to-brain delivery method offers numerous benefits, including fewer side effects and avoidance of unwanted rapid metabolism.
“This feature can potentially be exploited to deliver drugs through the nasal mucosa,” Dr. Parekh stated in a news release. “The longer-term goal is to develop Sol-gels as safe, reliable delivery systems for cannabinoid extracts across a range of disease indications.”
PreveCeutical’s Sol-gel CBD-based technology could provide a clinical benefit for patients seeking relief for any number of medical indications, such as pain, inflammation, seizures and neurological disorders. In addition to its ease of application, a CBD-based Sol-gel will stay in the nasal passages longer, slowly releasing the CBD while keeping it active for up to seven days.
The legal cannabis market, which includes CBD-based therapy, is projected to reach $24 billion by 2025, according to a report published in Hemp Business Journal (http://nnw.fm/ohYZ3), with an overwhelming number of those surveyed stating that CBD therapy was being used for depression or pain. An analysis by Stratistics MRC also shows that the global pain management, drugs and devices market is expected to reach $61.52 billion by 2023 as the population ages and improving health care technologies and alternative therapies attract more attention (http://nnw.fm/r4fVC).
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Universally-patient friendly, meaning formulations that can be used in children and adults alike
- Transport of drugs through blood-brain barrier marks top priority for researchers
- North American legal cannabis market projected at more than $24 billion by 2021
- Global market for pain management, drugs and devices estimated at over $61 billion by 2023
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is a Vancouver-based health sciences company dedicated to research and development of innovative, organic and Nature Identical™ options for preventive and curative therapies for a wide array of devastating medical conditions. Developing what the company believes will be the first U.S. Food and Drug Administration-approved cannabidiol (CBD)-soluble gel product to deliver the therapeutic benefits of CBD directly to the central nervous system (CNS) is a top priority for PreveCeutical Chief Researcher Officer Dr. Harry Parekh, who is based at the University of Queensland, Australia, School of Pharmacy (http://nnw.fm/DciL0).
Breaking through the blood-brain barrier, which functions as the last line of defense for the body’s most vital organ, is a prime research target, as noted in a May 2017 article published by The Pharmaceutical Journal (http://nnw.fm/qDr3K). Delivering life-saving drugs directly to the brain to treat complex brain disorders such as Alzheimer’s, Parkinson’s, epilepsy and depression in a safe and effective manner continues to be a major topic of discussion and compelling research around the world (http://nnw.fm/Suw9U). The need for a solution, a way to present a medication directly where it will do the most good with the fewest side effects, is a key driver for Dr. Parekh and his research collaborators as they continue their work on cannabinoids, formulating them into Sol-gels for further testing.
PreveCeutical’s proprietary Sol-gel formulations begin as a liquid that is administrated into the nose, which then forms a gel as it is warmed in the nasal cavity where it can then be absorbed. This effectively bypasses the stomach and intestines – eliminating first pass metabolism – and may dramatically improve bioavailability, even compared to nasal sprays and newer delivery systems. This nose-to-brain delivery method offers numerous benefits, including fewer side effects and avoidance of unwanted rapid metabolism.
“This feature can potentially be exploited to deliver drugs through the nasal mucosa,” Dr. Parekh stated in a news release. “The longer-term goal is to develop Sol-gels as safe, reliable delivery systems for cannabinoid extracts across a range of disease indications.”
PreveCeutical’s Sol-gel CBD-based technology could provide a clinical benefit for patients seeking relief for any number of medical indications, such as pain, inflammation, seizures and neurological disorders. In addition to its ease of application, a CBD-based Sol-gel will stay in the nasal passages longer, slowly releasing the CBD while keeping it active for up to seven days.
The legal cannabis market, which includes CBD-based therapy, is projected to reach $24 billion by 2025, according to a report published in Hemp Business Journal (http://nnw.fm/ohYZ3), with an overwhelming number of those surveyed stating that CBD therapy was being used for depression or pain. An analysis by Stratistics MRC also shows that the global pain management, drugs and devices market is expected to reach $61.52 billion by 2023 as the population ages and improving health care technologies and alternative therapies attract more attention (http://nnw.fm/r4fVC).
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)